Neurocrine Biosciences (NBIX) Projected to Post Earnings on Tuesday

Neurocrine Biosciences (NASDAQ:NBIX) will likely be releasing its Q3 2025 results after the market closes on Tuesday, October 28th. Analysts expect Neurocrine Biosciences to post earnings of $1.55 per share and revenue of $746.6050 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The firm had revenue of $687.50 million for the quarter, compared to analysts’ expectations of $653.09 million. During the same period in the prior year, the business posted $1.63 earnings per share. The company’s revenue was up 16.5% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Stock Up 0.2%

Shares of NBIX opened at $144.00 on Friday. The business’s 50-day moving average price is $139.94 and its 200-day moving average price is $127.79. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $154.61. The stock has a market cap of $14.28 billion, a PE ratio of 42.60, a P/E/G ratio of 0.98 and a beta of 0.21.

Wall Street Analyst Weigh In

Several research analysts have recently commented on NBIX shares. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Morgan Stanley upped their target price on Neurocrine Biosciences from $163.00 to $168.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. UBS Group increased their price objective on Neurocrine Biosciences from $188.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Citigroup started coverage on Neurocrine Biosciences in a report on Tuesday, October 21st. They set a “buy” rating and a $175.00 target price for the company. Finally, The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a report on Thursday, July 10th. They set a “buy” rating and a $182.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $164.32.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the transaction, the director owned 514,596 shares in the company, valued at approximately $65,050,080.36. This represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. State of Wyoming increased its stake in Neurocrine Biosciences by 71.2% during the second quarter. State of Wyoming now owns 1,671 shares of the company’s stock worth $210,000 after acquiring an additional 695 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at $215,000. Acadian Asset Management LLC grew its stake in shares of Neurocrine Biosciences by 14.3% in the first quarter. Acadian Asset Management LLC now owns 3,054 shares of the company’s stock valued at $337,000 after buying an additional 383 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at $579,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.